Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $38.9970 (1.66%) ($35.7000 - $39.2000) on Thu. Nov. 16, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.37% (three month average) | RSI | 53 | Latest Price | $38.9970(1.66%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.9% a day on average for past five trading days. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKK(8%) KWEB(8%) MCHI(8%) QQQ(8%) SKYY(8%) | Factors Impacting HTBX price | HTBX will decline at least -1.685% in a week (0% probabilities). VCSH(-9%) VIXM(-5%) CEMB(-5%) BNDX(-4%) XLU(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.685% (StdDev 3.37%) | Hourly BBV | 0 () | Intraday Trend | 2.4% | | | |
|
Resistance Level | $41.52 | 5 Day Moving Average | $40.46(-3.62%) | 10 Day Moving Average | $41.52(-6.08%) | 20 Day Moving Average | $41.52(-6.08%) | To recent high | -26.6% | To recent low | 17.3% | Market Cap | $4.291b | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |